Clinical Care Options Oncology - Head and Neck Cancer http://clinicaloptions.com/oncology.aspx New treatment data and educational activities for Oncology and Hematology Clinicians en-us Clinical Care Options Oncology - Head and Neck Cancer http://images.imedoptions.com/img.asp?img=cco/CCO_ONC_RSS.gif http://clinicaloptions.com/oncology.aspx Expert Analysis from Chicago: Head and Neck Cancer http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Head%20and%20Neck%20Cancer/Head%20and%20Neck%20Cancer.aspx James A. Bonner, MD, Marshall Posner, MD, and Everett Vokes, MD, provide analysis of new data presented in Chicago. Intensity-Modulated Radiotherapy Superior to Conventional Radiation Therapy in Improving Local Control and Preserving Salivary Function in Stage II Nasopharyngeal Cancer http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Head%20and%20Neck%20Cancer/Capsules/6036.aspx Results of a phase II study in patients with T2/N0-T2/N1 nasopharyngeal carcinoma suggest that of IMRT provides superior local disease control and salivary gland function compared with conventional radiotherapy. Neoadjuvant Chemotherapy Prior to Chemoradiation Tolerable and May Improve Survival Over Chemoradiotherapy Alone in Locally Advanced Nasopharyngeal Cancer http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Head%20and%20Neck%20Cancer/Capsules/6037.aspx Phase II study suggests that neoadjuvant chemotherapy followed by cisplatin-based chemoradiotherapy is well tolerated with manageable toxicity and may offer a survival benefit over chemoradiotherapy alone in patients with locally advanced nasopharyngeal cancer. Chemotherapy Alone After Induction Maintains Function and Does Not Impact Survival in Patients With Laryngopharyngeal Cancer http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Head%20and%20Neck%20Cancer/Capsules/6039.aspx Platinum-based induction chemotherapy followed treatment with chemotherapy alone effective and less toxic for patients with laryngopharyngeal squamous cell carcinoma. Vandetanib Provides Clinical Benefit for Advanced Hereditary Medullary Thyroid Cancer http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Head%20and%20Neck%20Cancer/Capsules/6018T.aspx Improved disease control with manageable toxicity in phase II trial results of vandetanib in patients with advanced hereditary medullary thyroid cancer. Sorafenib Active in Patients With Metastatic Thyroid Cancer http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Head%20and%20Neck%20Cancer/Capsules/6019T.aspx In preliminary results of a phase II study in patients with metastatic thyroid cancer, sorafenib produced a clinical benefit (partial response or stable disease). Cetuximab Added to Platinum-Based Chemotherapy Significantly Prolongs Survival for Patients With Recurrent or Metastatic SCCHN http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Head%20and%20Neck%20Cancer/Capsules/60XX.aspx Interim analysis of the phase III EXTREME trial in patients with recurrent or metastatic SCCHN shows prolonged survival with addition of cetuximab to platinum/5-FUbased therapies. Motesanib Diphosphate Active and Tolerable in Patients With Progressive Differentiated Thyroid Cancer http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Head%20and%20Neck%20Cancer/Capsules/6017.aspx Significant durable partial response and stable disease rates with motesanib in a phase II study of patients with thyroid cancer Cetuximab Combined With Induction Chemotherapy and Chemoradiation Produces Complete Pathological Responses in Patients With Operable Head and Neck Cancer http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Head%20and%20Neck%20Cancer/Capsules/6015.aspx The addition of cetuximab to chemotherapy and chemoradiation is associated with complete pathological responses in patients with advanced operable squamous cell carcinoma of the head and neck. Improved Survival Following Chemoradiation for Patients With Head and Neck Squamous Cell Carcinoma Positive for Human Papillomavirus http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Head%20and%20Neck%20Cancer/Capsules/6000.aspx Multicenter, prospective, phase II ECOG trial shows chemoradiation improves survival in patients with head and neck squamous cell carcinomas positive for human papillomavirus. Alternating Chemotherapy/Radiotherapy Does Not Improve Functional Larynx Preservation or Survival Rates for Patients With Resectable Hypopharynx or Larynx Cancer http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Head%20and%20Neck%20Cancer/Capsules/LBA6016.aspx Alternating chemotherapy and radiotherapy in patients with resectable hypopharynx and larynx cancer preserves larynx function, but this does not translate into superior survival for patients with a functional larynx compared with standard sequential chemotherapy and radiotherapy. Intratumoral EGFR Antisense DNA Active and Safe in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Head%20and%20Neck%20Cancer/Capsules/6009.aspx In a phase I trial, intratumoral EGFR antisense DNA showed preliminary activity and was safe without dose-limiting toxicity in patients with advanced SCCHN refractory to chemotherapy, surgery, and/or radiotherapy. Taxane-Containing Induction Chemotherapy With Radiotherapy and Concurrent Cisplatin Toxic but Feasible in Advanced-Stage HNSCC http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Head%20and%20Neck%20Cancer/Capsules/6014.aspx In patients with advanced-stage HNSCC, administration of a taxane-containing induction chemotherapy, concurrent cisplatin chemotherapy, and accelerated fractionation/concomitant boost radiotherapy was feasible but toxic Axitinib Active and Well Tolerated in Advanced Thyroid Cancer http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Head%20and%20Neck%20Cancer/Capsules/6008T.aspx Axitinib, an inhibitor of VEGFR, demonstrated a significant partial response rate in patients with advanced thyroid cancer No Correlation Between Survival and EGFR, VEGF, and p53 Overexpression in Head and Neck Squamous Cell Cancer http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Head%20and%20Neck%20Cancer/Capsules/6010.aspx In an analysis of GORTEC 99-02, no relationship was observed between survival rates and overexpression of EGFR, p53, and VEGF in patients with HNSCC DCE-MRI May Predict Treatment Response in HNSCC Patients http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Head%20and%20Neck%20Cancer/Capsules/6007.aspx A prospective pilot study indicates that DCE-MRI can predict response among patients with HNSCC patients proceeding to chemoradiation.